QRON / Qrons Inc. - SEC-arkivering, Årsberetning, Fuldmagtserklæring

EX-99.1

EXHIBIT 99.1

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 (July 10, 2025) QRONS INC. (Exact name of registrant as specified in its charter) Wyoming 000-55800 81-3623646 (State or other jurisdiction of incorporation) (Commission

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-55800 ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-55800 ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For the period ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transit

Warrant dated February 20, 2025, issued by the Company to Quick Capital, LLC

EXHIBIT 10.50 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS

Subsidiaries of the Company

EXHIBIT 21.1 Qrons Inc. List of Subsidiaries (as of April 15, 2025) Name of Subsidiary Domicile Percent Ownership First Person Ltd. Alberta, Canada 100% First Person Inc. Delaware, USA 100% owned by First Person Ltd.

Secured Convertible Promissory Note dated February 20, 2025, $55,555.56 principal amount, in favor of BC Funds, LLC

EXHIBIT 10.47 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

Warrant dated February 20, 2025, issued by the Company to Leonite Fund I, LP

EXHIBIT 10.54 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS

Note Purchase Agreement dated April 10, 2025, between the Company and Leonite Fund I, LP

EXHIBIT 10.44 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of April 8, 2025, (the “Execution Date”), is entered into by and between QRONS INC., a Wyoming corporation (the “Company”), and LEONITE FUND I, LP (the “Buyer”). Each capitalized term used herein shall have the meaning ascribed thereto in Section 10 below, or as otherwise defined herein. WHEREAS, the Co

Note Purchase Agreement dated February 25, 2025, between the Company and BC Funds, LLC

EXHIBIT 10.42 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of February 25, 2025, (the “Execution Date”), is entered into by and between QRONS INC., a Wyoming corporation (the “Company”), and BC FUNDS, LLC (the “Buyer”). Each capitalized term used herein shall have the meaning ascribed thereto in Section 10 below, or as otherwise defined herein. WHEREAS, the Com

Warrant dated February 20, 2025, issued by the Company to BC Funds, LLC

EXHIBIT 10.52 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS

Note Purchase Agreement dated February 20, 2025, between the Company and Quick Capital, LLC

EXHIBIT 10.40 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of February 20, 2025, (the “Execution Date”), is entered into by and between QRONS INC., a Wyoming corporation (the “Company”), and QUICK CAPITAL, LLC, a Wyoming limited liability company (the “Buyer”). Each capitalized term used herein shall have the meaning ascribed thereto in Section 10 below, or as

Warrant dated February 20, 2025, issued by the Company to Cory Rosenberg

EXHIBIT 10.51 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS

Secured Convertible Promissory Note dated February 20, 2025, $55,555.56 principal amount, in favor of Quick Capital, LLC

EXHIBIT 10.45 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

Note Purchase Agreement dated February 20, 2025, between the Company and Cory Rosenberg

EXHIBIT 10.41 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of February 24, 2025, (the “Execution Date”), is entered into by and between QRONS INC., a Wyoming corporation (the “Company”), and CORY ROSEBERG (the “Buyer”). Each capitalized term used herein shall have the meaning ascribed thereto in Section 10 below, or as otherwise defined herein. WHEREAS, the Com

Form of Security Agreement

EXHIBIT 10.55 SECURITY AGREEMENT THIS SECURITY AGREEMENT (this “Agreement”), dated as of , 2025, is by and between QRONS INC., a Wyoming corporation (the “Grantor”), and (the “Secured Party”). WHEREAS, on the date hereof, the Grantor has issued its $ Secured Convertible Promissory Note (the “Note”) to the Secured Party pursuant to that certain Note Purchase Agreement of even date herewith (as amen

Secured Convertible Promissory Note dated February 20, 2025, $110,000.00 principal amount, in favor of Leonite Fund I, LP

EXHIBIT 10.49 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

Secured Convertible Promissory Note dated February 20, 2025, $55,555.56 principal amount, in favor of Cory Rosenberg

EXHIBIT 10.46 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55800 QRONS INC. (Exact name of re

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 (March 29, 2025) QRONS INC. (Exact name of registrant as specified in its charter) Wyoming 000-55800 81-3623646 (State or other jurisdiction of incorporation) (Commissio

Letter from OLAYINKA OYEBOLA & CO. dated April 1, 2025

EXHIBIT 16.1 April 1, 2025 United States Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.E. Washington, D.C. 20549 Re: Qrons, Inc. Dear Sirs/Madams, We have read the statements under item 4.01 in the Form 8-K dated April 1, 2025, of Qrons, Inc. to be filed with the Securities and Exchange Commission and we agree with such statements therein as related to our firm.

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-55800

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-55800 ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For period ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transiti

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 (March 12, 2025) QRONS INC. (Exact name of registrant as specified in its charter) Wyoming 000-55800 81-3623646 (State or other jurisdiction of incorporation) (Commissi

Letter from Green Growth CPAS dated March 24, 2025

EXHIBIT 16.1 March 25, 2025 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Qrons Inc.’s statements included under Item 4.01 of its Form 8-K dated March 25, 2025. We agree with the statements concerning our Firm under Item 4.01. We are not in a position to agree or disagree with other statements containe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14F-1 INFORMATION STATEMENT PURSUANT TO SECTION 14(F) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14F-1 THEREUNDER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14F-1 INFORMATION STATEMENT PURSUANT TO SECTION 14(F) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14F-1 THEREUNDER Qrons Inc. (Exact name of registrant as specified in its charter) Wyoming 81-3623646 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 611 N. Brand Bo

Plan and Agreement of Merger between and among Qrons Inc., Primary Merger Sub, Inc. and First Person Ltd.

EXHIBIT 2.1 PLAN AND AGREEMENT OF MERGER Plan and Agreement of Merger1, dated as of January 1, 2025 (the “Agreement”), among Qrons Inc., a Wyoming corporation (“Parent”), Primary Merger Sub, Inc., a Colorado corporation wholly owned by Parent (“Merger Sub”), and First Person Ltd., an Alberta, Canada corporation (“Target”) (Merger Sub and Target being hereinafter collectively referred to as the “Co

Articles of Amendment filed January 2, 2025 (Restatement of Certificate of Designation of Series A Preferred Stock and Certificate of Designation of Series B Convertible Preferred Stock.

EXHIBIT 3.1

Anti-Dilution Agreement among the Company, Jonah Meer, Decagon LLC, d/b/a CubeSquare LLC, Ido Merfeld and First Person Ltd.

EXHIBIT 10.1 ANTI-DILUTION AGREEMENT This Anti-Dilution Agreement (the “Agreement”) is dated as of January 31, 2024, to be effective January 1, 2025 (the “Effective Date”), and is by and among Qrons Inc., a Wyoming corporation (the “Company”), First Person Ltd., an Alberta, Canada, corporation (“First Person”), Jonah Meer (“Meer”), Decagon LLC, d/b/a CubeSquare LLC, a Delaware limited liability co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 (January 31, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 (January 31, 2025) QRONS INC. (Exact name of registrant as specified in its charter) Wyoming 000-55800 81-3623646 (State or other jurisdiction of incorporation) (Comm

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 (January 15, 2025) QRONS INC. (Exact name of registrant as specified in its charter) Wyoming 000-55800 81-3623646 (State or other jurisdiction of incorporation) (Comm

Agreement and Plan of Merger among the Company, Primary Merger Sub, Inc. and First Person, Ltd.

EXHIBIT 10.1 PLAN AND AGREEMENT OF MERGER Plan and Agreement of Merger1, dated as of January 1, 2025 (the “Agreement”), among Qrons Inc., a Wyoming corporation (“Parent”), Primary Merger Sub, Inc., a Colorado corporation wholly owned by Parent (“Merger Sub”), and First Person Ltd., an Alberta, Canada corporation (“Target”) (Merger Sub and Target being hereinafter collectively referred to as the “C

Amended Designation of Series A Preferred Stock and Designation of Series B Convertible Preferred Stock (25)

EXHIBIT 3.1

Termination Notice dated October 28, 2024

EXHIBIT 10.38 October 28, 2024 VIA EMAIL DELIVERY: Professor Benjamin Sredni Professor Michael Albeck Adv. Avichai Isachar Adv. Hananel Levy Re: License term Sheet Agreement effective July 17, 2023 ( the “Agreement”) Gentlemen: Pursuant to Paragraph 12 of the above captioned Agreement, Notice is hereby given that the Agreement is terminated. In addition, your memberships in the Scientific Advisory

Notice to Ariel Scientific Innovations Ltd. dated October 28, 2024

EXHIBIT 10.39 October 28, 2024 VIA EMAIL DELIVERY: Mr. Adiv Baruch, Chairman Mr. Danny Hardon, CEO Ariel Scientific Innovations Ltd. Ariel University Ariel 40070 Israel Re: Royalty and License Fee Sharing Agreement dated as of November 30, 2019 ( the “Agreement”) Gentlemen: An Exit Event as defined by the above caption Agreement has occurred whereby Qrons has agreed to enter into a merger agreemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55800 QRONS INC. (Exact

Term Sheet dated October 16, 2024

EXHIBIT 10.37 October 16, 2024 This Term Sheet describes the proposed terms and conditions under which First Person Ltd. (“FP”) and/or its affiliates enter into a definitive merger agreement with Qrons Inc. (“Qrons”) a U.S. publicly traded company trading on the OTCQB Venture Market under the trading symbol QRON. The parties agree that this Term Sheet supersedes and replaces any and all prior oral

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 QRONS INC. (Exact name of registrant as specified in its charter) Wyoming 000-55800 81-3623646 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55800 QRONS INC. (Exact name

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-55800

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-55800 ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For period ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55800 QRONS INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55800 QRONS INC. (Exact name of re

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-55800

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-55800 ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For period ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transiti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 ☐ TRANSITION REPORT PURSUAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact

Letter from Pinnacle Accountancy Group of Utah a dba of Heaton & Company, PLLC

EXHIBIT 16.1 November 3, 2023 Securities and Exchange Commission (the “Commission”) 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentleman: We are the former independent registered public accounting firm for Qrons Inc. (the “Company”). We have read the statements made by the Company, which were provided to us and which we understand will be filed with the Commission pursuant to Item 4.01

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 QRONS INC. (Exact name of registrant as specified in its charter) Wyoming 000-55800 81-3623646 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact name

June 15, 2023 Letter Agreement between the Company and Quick Capital LLC (23)

EXHIBIT 10.36 Leter of understanding between Qrons Inc. and Quick Capital, LLC By this leter agreement “Agreement” dated as of June 15, 2023, between Qrons Inc. Inc (the “Company”) and Quick Capital, LLC (the “Investor”) the parties agree as follows: 1. The Maturity Date of the $115,000 Convertible Promissory Note dated June 15, 2021 which had been extended from June 15, 2022 to June 15, 2023 is h

Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Trauma

EXHIBIT 99.1 Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Traumatic Brain Injuries NEW YORK, NY / ACCESSWIRE / July 20, 2023 / Qrons Inc. (OTCQB:QRON) announced today the signing of a License Agreement

License Agreement Term Sheet dated July 17, 2023 (22)

EXHIBIT 10.35 License Agreement Term Sheet Parties Qrons Inc., a Wyoming Corporation Dr. Ido Merfeld Professors Benjamin Sredni & Michael Albeck (“The Professors”) Background: 1. This Agreement shall commence on 17/07/2023 (“Effective Date”). 2. The Professors are the inventors of certain patents, applications, processes and possess certain related know-how particularly as to AS101 Tellurium based

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 (May 30, 2023)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 (May 30, 2023) QRONS INC. (Exact name of registrant as specified in its charter) Wyoming 000-55800 81-3623646 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact nam

Letter of understanding between QRONS, Inc and Quick Capital, LLC, dated December 7, 2022

EXHIBIT 10.34 Letter of understanding between QRONS, Inc and Quick Capital, LLC By this letter agreement “Agreement” dated December 7, 2022, between QRONS, Inc (the “Company”) and Quick Capital, LLC (the “Investor”) the parties agree as follows: 1. The Maturity Date of the $115,000 Convertible Promissory Note dated June 15, 2021 (Note”) is hereby extended from June 15, 2022, to June 15, 2023. The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55800 QRONS INC. (Exact name of re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 ☐ TRANSITION REPORT PURSUAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact name

PROSPECTUS QRONS INC. Offer of up to 2,500,000 shares of common stock offered by the Company and 3,651,429 shares offered by Selling Shareholders

424B3 1 form424b.htm 424B3 As filed pursuant to Rule 424(b)(3) Registration No. 333-261437 PROSPECTUS QRONS INC. Offer of up to 2,500,000 shares of common stock offered by the Company and 3,651,429 shares offered by Selling Shareholders We are offering to sell up to 2,500,000 shares of common stock in a self-underwritten primary offering at a fixed price of $0.70 per share for a period of two year

As filed with the Securities and Exchange Commission on March 18 , 2022

POS AM 1 posam.htm POS AM As filed with the Securities and Exchange Commission on March 18 , 2022 Registration No. 333-261437 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QRONS INC. (Exact name of registrant as specified in its charter) Wyoming 2836 81-3623646 (State or o

Filing Fee Table

EX-FILING FEES 3 ex107.htm FILING FEES TABLE Exhibit 107 Calculation of Filing Fee Tables (1) Form S-1 (Form Type) Qrons Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55800 QRONS INC. (Exact name of re

PROSPECTUS QRONS INC.

424B3 1 form424b3.htm 424B3 As filed pursuant to Rule 424(b)(3) Registration No. 333-261437 PROSPECTUS QRONS INC. Offer of up to 2,500,000 shares of common stock offered by the Company and 3,651,429 shares offered by Selling Shareholders We are offering to sell up to 2,500,000 shares of common stock in a self-underwritten primary offering at a fixed price of $0.70 per share for a period of two yea

QRONS INC. 28-10 Jackson Avenue #26N Long Island City, New York 11101

QRONS INC. 28-10 Jackson Avenue #26N Long Island City, New York 11101 January 6, 2022 BY EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Office of Natural Resources 100 F Street, N.E. Washington, D.C. 20549 Attention: Christine Westbrook Office of Life Sciences Re: Qrons Inc. Registration Statement on Form S-1 (File Number 333-261437) Dear Ms. Westbrook: In accordance w

Form of Subscription Agreement

Exhibit 10.34 Qrons Inc. 28-10 Jackson Avenue #26N Long Island City, New York 11101 Attn: Jonah Meer, Chief Executive Officer QRONS INC. SUBSCRIPTION CONFIRMATION The undersigned, intending to be legally bound, hereby irrevocably subscribes for and agrees to purchase shares of common stock, par value $0.0001 per share (?Common Stock?) of Qrons Inc, a Wyoming corporation (the ?Corporation?), for a

Brenner & Associates, PLLC 1 Kensington Gate Great Neck, New York 11021 Telephone: (917) 282-4272 [email protected]

Brenner & Associates, PLLC 1 Kensington Gate Great Neck, New York 11021 Telephone: (917) 282-4272 nbrenneresq@gmail.

As filed with the Securities and Exchange Commission on January 3, 2022

As filed with the Securities and Exchange Commission on January 3, 2022 Registration No.

Fifth Amendment to $10,000 8% Convertible Debenture, dated October 7, 2021

FIFTH AMENDMENT TO 8% CONVERTIBLE DEBENTURE: This Fifth Amendment to the 8% Convertible Debenture, dated September 1, 2016, as amended by First Amendment to 8% Convertible Debenture, dated September 28, 2017, Second Amendment dated September 9, 2018, Third Amendment dated November 6, 2019, and Fourth Amendment dated November 15, 2020, made by BioLabMart Inc.

Fourth Amendment to $15,000 8% Convertible Debenture, dated October 7, 2021

FOURTH AMENDMENT TO 8% CONVERTIBLE DEBENTURE: This Fourth Amendment to the 8% Convertible Debenture, dated September 27, 2017, as amended by the First Amendment to the 8% Convertible Debenture, dated September 9, 2018, Second Amendment dated November 6, 2019, and Third Amendment dated November 15, 2020, made by Qrons Inc.

As filed with the Securities and Exchange Commission on December 1, 2021

As filed with the Securities and Exchange Commission on December 1, 2021 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact name

Note Purchase Agreement, dated June 15, 2021, between the Company and Quick Capital, LLC (19)

NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this ?Agreement?), dated as of June 15, 2021, (the ?Execution Date?), is entered into by and between QRONS INC.

Common Stock Purchase Warrant, dated June 15, 2021 issued to Quick Capital, LLC (19)

NEITHER THE ISSUANCE OF THE SECURITIES REPRESENTED HEREBY NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2021 QRONS INC.

Convertible Promissory Note, dated June 15, 2021, issued to Quick Capital, LLC (19)

NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION ST

Certification of the Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

Exhibit 32 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, Jonah Meer, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer) of Qrons Inc. (the "Company"), certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. S

Certification of the Principal Executive Officer and Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 31 Certification Pursuant to pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended I, Jonah Meer, (Principal Executive Officer and Principal Financial and Accounting Officer), certify that: 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact

Section 1350 Certifications of Chief Executive Officer and Chief Financial Officer

Exhibit 32 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, Jonah Meer, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer) of Qrons Inc. (the "Company"), certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. S

Rule 13a-14(a)/15d-14(a) Certifications of Chief Executive Officer and Chief Financial Officer

Exhibit 31 Certification Pursuant to pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended I, Jonah Meer, (Principal Executive Officer and Principal Financial and Accounting Officer), certify that: 1.

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55800 QRONS INC. (Exact name of re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934 QRONS INC. (Name of Issuer) Shares of Common Stock, $0.0001 Par Value (Title of Class of Securities) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934 QRONS INC. (Name of Issuer) Shares of Common Stock, $0.0001 Par Value (Title of Class of Securities) 74737F101 (CUSIP Number) Jonah Meer Chief Executive Officer 50 Battery Place, #7T New York, New York 10280 (212)-945-2080 (Name, Address and Telephone N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934 QRONS INC. (Name of Issuer) Shares of Common Stock, $0.0001 Par Value (Title of Class of Securities) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934 QRONS INC. (Name of Issuer) Shares of Common Stock, $0.0001 Par Value (Title of Class of Securities) 74737F101 (CUSIP Number) Jonah Meer Chief Executive Officer 50 Battery Place, #7T New York, New York 10280 (212)-945-2080 (Name, Address and Telephone N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Ex

Certification of the Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer) pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

Exhibit 32 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, Jonah Meer, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer) of Qrons Inc. (the "Company"), certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. S

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact n

Certification of the Principal Executive Officer and Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 31 Certification Pursuant to pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended I, Jonah Meer, (Principal Executive Officer and Principal Financial and Accounting Officer), certify that: 1.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact

Form of Securities Purchase Agreement for 8% Convertible Promissory Notes (18)

EX-10.27 4 ex1027.htm FORM OF SECURITIES PURCHASE AGREEMENT FOR 8% CONVERTIBLE PROMISSORY NOTES SECURITIES PURCHASE AGREEMENT This securities purchase agreement (this “Agreement”) is made by and between Qrons Inc., a Wyoming corporation (the "Company"), and , a citizen and resident of the State of (the “Undersigned”) as of December , 2019. The Undersigned hereby irrevocably agrees to purchase the

QRON / Qrons Inc. 10-K - Annual Report - 10-K

10-K 1 form10k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55800 QRON

Third Amendment to Services Agreement, dated December 8, 2019, between the Company and Ariel Scientific Innovations Ltd.(18)

THIRD AMENDMENT TO SERVICES AGREEMENT This Third Amendment to the Services Agreement, dated December 8, 2019, to the Services Agreement, dated December 14, 2017 between Ariel Scientific Innovations Ltd.

Form of 8% Convertible Promissory Note (18)

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS (COLLECTIVELY, THE “LAWS”).

Description of Securities (18)

DESCRIPTION OF COMMON STOCK As of the date of the Annual Report on Form 10-K of which this exhibit is a part, Qrons Inc.

QRON / Qrons Inc. / Merfeld Ido - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 QRONS INC. (Name of Issuer) Shares of Common Stock, $0.0001 Par Value (Title of Class of Securities) 74737F101 (CUSIP Number) Jonah Meer Chief Executive Officer 50 Battery Place, #7T New York, New York 10280 (212)-945-2080 (Name, Address and Telephone Num

QRON / Qrons Inc. / Meer Jonah - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 QRONS INC. (Name of Issuer) Shares of Common Stock, $0.0001 Par Value (Title of Class of Securities) 74737F101 (CUSIP Number) Jonah Meer Chief Executive Officer 50 Battery Place, #7T New York, New York 10280 (212)-945-2080 (Name, Address and Telephone Num

Unregistered Sales of Equity Securities

8-K 1 form8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 17, 2019 QRONS INC. (Exact name of registrant as specified in its charter) Wyoming (State or other jurisdiction of incorporation) 000-55800 81-3623646 (Com

Royalty and License Fee Sharing Agreement, dated November 30, 2019, between the Company and Ariel Scientific Innovations Ltd. (17)

ROYALTY AND LICENSE FEE SHARING AGREEMENT This Royalty and License Fee Sharing Agreement (the “Agreement”) is entered into as of November 30, 2019 (the “Effective Date”), between Qrons Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2019 QRONS INC.

QRON / Qrons Inc. 10-Q - Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Ex

First Amendment to Sponsored Research Agreement, dated November 4, 2019, between the Company and Trustees of Dartmouth College (16)

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED FIRST AMENDMENT TO DARTMOUTH COLLEGE SPONSORED RESEARCH AGREEMENT NO.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 form8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2019 QRONS INC. (Exact name of registrant as specified in its charter) Wyoming (State or other jurisdiction of incorporation) 000-55800 81-3623646 (Comm

Intellectual Property License Agreement, entered into on October 2,2019, between the Company and Trustees of Dartmouth College (15)

DARTMOUTH COLLEGE INTELLECTUAL PROPERTY LICENSE AGREEMENT This License Agreement (this “Agreement”) is made by and between Qrons Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 2, 2019 QRONS INC.

QRON / Qrons Inc. 10-Q - Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact n

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

8-K 1 form8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2019 QRONS INC. (Exact name of registrant as specified in its charter) Wyoming (State or other jurisdiction of incorporation) 000-55800 81-3623646 (Commis

Qrons Announces Upgrade to OTCQB Market Trading Continues Under Ticker "QRON"

Qrons Announces Upgrade to OTCQB Market Trading Continues Under Ticker "QRON" New York, NY, August 12, 2019 (GLOBE NEWSWIRE) - via NEWMEDIAWIRE– Qrons Inc.

Services Agreement, dated August 8, 2019, between the Company and PCG Advisory, Inc. (14)

SERVICES AGREEMENT This Agreement (this "Agreement") is made and entered into on August 8th, 2019, by and between PCG Advisory, Inc.

QRONS APPOINTS VETERAN U.S. BASED BIOTECH EXECUTIVE DR. JOHN N. BONFIGLIO TO LEAD IND AND CAPITAL MARKETS RELATED ACTIVITIES

QRONS APPOINTS VETERAN U.S. BASED BIOTECH EXECUTIVE DR. JOHN N. BONFIGLIO TO LEAD IND AND CAPITAL MARKETS RELATED ACTIVITIES June 27, 2019 NEW YORK, NY. (GLOBE NEWSWIRE) – VIA NEWMEDIAWIRE. Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries ("TBIs"), including concussions and penet

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 25, 2019 QRONS INC.

Term Sheet, effective July 1, 2019, between the Company and John Bonfiglio (13)

TERM SHEET EFFECTIVE AS OF JULY 1, 2019: BETWEEN QRONS INC. AND DR. JOHN N. BONFIGLIO Dr. John N. Bonfiglio ("JB") shall be employed as the Chief Operating Officer ("COO") of Qrons Inc. ("The Company"). As COO JB will be responsible for: 1: Guiding and preparing the Company for an IND/BLA filing including hiring and managing the appropriate experts and vendors to expedite the IND/BLA process. 2: M

QRON / Qrons Inc. 10-Q Quarterly Report 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2019 QRONS INC.

$50,000 8% Demand Promissory Note, dated May 1, 2019 issued to CubeSquare, LLC (12)

DEMAND PROMISSORY NOTE $ 50,000.00 New York, New York May 1, 2019 FOR VALUE RECEIVED, Qrons, Inc., a Wyoming corporation, having an address at 50 Battery Place, #7T, New York, New York 10280 ("Maker"), promises to pay to the order of CubeSquare, LLC, a Delaware limited liability company, and having an address at 1900 Purdy avenue, #1907, Miami Beach, FL 33139("Payee") , or at such other place as t

First Amendment to Services Agreement, dated April 11, 2019 between the Company and Ariel Scientific Innovations Ltd. (11)

EX 10.19 FIRST AMENDMENT TO SERVICES AGREEMENT First Amendment to the Services Agreement entered into on March 6, 2018, between Ariel Scientific Innovations Ltd., a company organized under the laws of Israel ("Ariel"), and Qrons Inc., a Wyoming corporation (the "Company"). WHEREAS, the Company and Ariel are parties to the Services Agreement related to the services of Dr. Gadi Tugerman and his AU t

Services Agreement, dated March 6, 2018, between the Company and Ariel Scientific Innovations Ltd. (11)

EX 10.18 SERVICES AGREEMENT This Services Agreement (the "Agreement") is entered into as of this 6th day of March 2018 (the "Effective Date"), by and between Ariel Scientific Innovations Ltd (formerly known as Ariel R&D), a company organized under the laws of Israel with offices at Ariel University ("AU"), Ariel, Israel ("Ariel") and Qrons Inc. (formerly known as BioLabMart Inc.), a company formed

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2019 QRONS INC.

QRON / Qrons Inc. FORM10-K (Annual Report)

10-K 1 e1286form10k.htm FORM10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-5

Second Amendment to the $10,000 8% Convertible Debenture, dated September 9, 2018 (10)

Exhibit 10.17 SECOND AMENDMENT TO 8% CONVERTIBLE DEBENTURE: This Second Amendment to the 8% Convertible Debenture, dated September 1, 2016, as amended by First Amendment to 8% Convertible Debenture, dated September 28, 2017, made by BioLabMart Inc., now known as Qrons Inc. for the benefit of CubeSquare LLC in the amount of $10,000 (the “Debenture”) hereby amends the Debenture as follows: The matur

First Amendment to $15,000 8% Convertible Debenture, dated September 9, 2018 (10)

Exhibit 10.16 FIRST AMENDMENT TO 8% CONVERTIBLE DEBENTURE:

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 10, 2018 QRONS INC.

Second Amendment to Services Agreement, dated December 12, 2018, between the Company and Ariel Scientific Innovations Ltd. (9)

Exhibit 10.14 SECOND AMENDMENT TO SERVICES AGREEMENT Second Amendment to the Services Agreement, entered into on December 14, 2017, as amended by First Amendment to Services Agreement, dated April 12, 2018 (collectively, the "Services Agreement") between Ariel Scientific Innovations Ltd., a company organized under the laws of Israel ("Ariel"), and Qrons Inc., a Wyoming corporation (the "Company").

QRON / Qrons Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (E

QRON / Qrons Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact

Qrons And Dartmouth College Enter into One Year Sponsored Research Agreement

Qrons And Dartmouth College Enter into One Year Sponsored Research Agreement Sponsored Research Agreement will allow for continued research in developing innovative 3D printable, bio compatible advanced materials and stem cell delivery techniques for Qrons' traumatic brain injury treatment.

Sponsored Research Agreement, made as of July 12, 2018, between the Company and Trustees of Dartmouth College (8)

DARTMOUTH COLLEGE SPONSORED RESEARCH AGREEMENT SPONSOR AGREEMENT NO. FP4991 This Sponsored Research Agreement ("Agreement") is made and is effective as of 07/12/2018 ("Effective Date") by and between Trustees of Dartmouth College, a non-profit, private educational and research institution under the laws of the State of New Hampshire ("Dartmouth") and Qrons Inc., a publicly traded, preclinical biot

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2018 QRONS INC.

QRON / Qrons Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 (Commission File Number) QRONS INC. (Exact

Professor Chenfeng Ke of Dartmouth College Joins Qrons Scientific Advisory Board

Professor Chenfeng Ke of Dartmouth College Joins Qrons Scientific Advisory Board MIAMI, FL / ACCESSWIRE / April 20, 2018 / Qrons Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2018 QRONS INC.

First Amendment to Services Agreement, dated April 12, 2018, between the Company and Ariel Scientific Innovations Ltd. (7)

EX-10.13 2 ex1013.htm FIRST AMENDMENT AGREEMENT TO SERVICES AGREEMENT, DATED APRIL 12, 2018, BETWEEN ARIEL SCIENTIFIC INNOVATIONS LTD. AND THE COMPANY FIRST AMENDMENT AGREEMENT FOR SERVICES AGREEMENT BETWEEN QRONS AND ASI This first amendment agreement (this "Amendment Agreement") is entered into as of April 12, 2018 (the "Amendment Effective Date"), by and between Qrons Inc., a company formed und

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2018 QRONS INC.

INVESTOR AND MEDIA CONTACT

FOR IMMEDIATE RELEASE INVESTOR AND MEDIA CONTACT Qrons Inc. Mr. Jonah Meer E: [email protected] P: 786-620-2140 QRONS EXERCISES DARTMOUTH OPTION Miami, Florida, March 26, 2018 /ACCESSWIRE/ – Qrons Inc. (OTCPK: QRON) ("Qrons" or the "Company") a preclinical biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries ("TBIs"

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 26, 2018 QRONS INC.

QRONS INC. 1,565,246 Shares of Common Stock $0.0001 par value 52,000 Shares of Common Stock $0.0001 par value Issuable upon Exercise of Warrants

As filed pursuant to Rule 424(b)(3) Registration No. 333-216650 PROSPECTUS QRONS INC. 1,565,246 Shares of Common Stock $0.0001 par value and 52,000 Shares of Common Stock $0.0001 par value Issuable upon Exercise of Warrants This prospectus relates to the offer and sale from time to time by the selling stockholders named in this prospectus of up to (i) 1,565,246 shares of our common stock $0.0001 p

QRON / Qrons Inc. POS AM

As filed with the Securities and Exchange Commission on March 15, 2018 Registration No.

QRON / Qrons Inc. AW

QRONS INC. 777 Brickell Ave Suite 500 Miami, Florida 33131 March 15, 2018 Securities and Exchange Commission Division of Corporation Finance 450 Fifth Street, N.W. Washington, DC 20549 December 9, 2002 Re: Application for withdrawal of Post-Amendment No.1 to Registration Statement on Form S-1/A (SEC File No. 333-216650) filed March 14, 2018 under form type S-1/A Ladies and Gentlemen: Pursuant to R

QRON / Qrons Inc. S-1/A

As filed with the Securities and Exchange Commission on March 14, 2018 Registration No.

$15,000 8% Convertible Debenture, dated September 27, 2017, between the Company and CubeSquare LLC(6)

Exhibit 10.11 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION

Form of Advisory Board Member Consulting Agreement (6)

Exhibit 10.12 ADVISORY BOARD MEMBER CONSULTING AGREEMENT THIS ADVISORY BOARD MEMBER CONSULTING AGREEMENT ("Agreement") is made as of , by and between Qrons Inc., a Wyoming corporation having an address at 777 Brickell Avenue, Suite 500, Miami, Florida, 33131 (the "Company"), and an individual with an address at (the "Advisor"). The Company and the Advisor may be referred to herein individually as

QRON / Qrons Inc. 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-55800 QRONS INC. (Exact name of re

First Amendment to $10,000 8% Convertible Debenture, dated September 28, 2017, between the Company and CubeSquare LLC (6)

Exhibit 10.10 FIRST AMENDMENT TO 8% CONVERTIBLE DEBENTURE: This First Amendment to the 8% Convertible Debenture dated September 1, 2016 made by BioLabMart Inc., now known as Qrons Inc. (the "Company") for the benefit of CubeSquare LLC in the amount of $10,000 (the "Debenture") hereby amends the Debenture as follows: 1) All references in the Debenture to ""BioLabMart Inc. shall be deleted and repla

Subscription Agreement, dated January 23, 2017, between the Company and Coventus Holdings SA (4) (5)

QRONS INC. SUBSCRIPTION AGREEMENT SECTION 1 1.1 Subscription. The undersigned, intending to be legally bound, hereby irrevocably subscribes for and agrees to purchase 312,500 shares of common stock, par value $.0001 per share of Qrons Inc. (the "Securities"), a Wyoming corporation (the "Company"), in an offshore transaction negotiated outside the U.S. and to be consummated and closed outside the U

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2018 QRONS INC.

Advisory Board Consulting Agreement, dated January 23, 2017, between the Company and Pavel Hilman (5)

ADVISORY BOARD MEMBER CONSULTING AGREEMENT THIS ADVISORY BOARD MEMBER CONSULTING AGREEMENT ("Agreement") is made as of January 23, 2018, by and between Qrons Inc.

INVESTOR AND MEDIA CONTACT

FOR IMMEDIATE RELEASE INVESTOR AND MEDIA CONTACT Qrons Inc. Mr. Jonah Meer E: [email protected] P: 786-620-2140 QRONS RAISES FUNDS TO FURTHER ITS GOALS, EXPANDS ADVISORY BOARD Miami, Florida, February 12, 2018 /ACCESSWIRE/ ? Qrons Inc. (OTCPK: QRON) ("Qrons " or the "Company") a preclinical biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus

Addendum #1 to License and Research Funding Agreement, effective December 13, 2017, between the Company and Ariel Scientific Innovations Ltd. (4)

ADDENDUM #1 TO LICENSE AND RESEARCH FUNDING AGREEMENT dated Dec. 14th, 2016 This addendum effective as of Dec. 13, 2017 ("the Addendum") Qrons Inc. (formerly BioLabMart Inc.), (" Qrons") and Ariel Scientific Innovations Ltd. (formerly Ariel University R&D Co., Ltd.), ("Ariel") (collectively the "Parties") Whereas, the Parties have entered into a Licenses and Research Funding Agreement (the "Agreem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2017 QRONS INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2017 QRONS INC.

Services Agreement, dated December 14, 2017, between Ariel Scientific Innovations Ltd., Ariel, Israel and the Company (4)

SERVICES AGREEMENT This Services Agreement is entered into as of this 14th day of December, 2017 (the "Effective Date"), by and between Ariel Scientific Innovations Ltd.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2017 QRONS INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2017 QRONS INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 Commission File Number QRONS INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 17, 2017 QRONS INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 17, 2017 QRONS INC.

Option Agreement between Trustees of Dartmouth College and the Company (3) **

OPTION AGREEMENT -Agreement # A-2017-0145 THIS OPTION AGREEMENT ("Agreement") dated as of September 27, 2017 ("Effective Date") is entered into by Trustees of Dartmouth College, hereinafter referred to as "Dartmouth", a non-profit educational and research institution with an address at 11 Rope Ferry Road, Hanover, NH 03755, and Qrons Inc.

Qrons Announces Signing of Option Agreement with Dartmouth College Agreement will allow for further research developing innovative 3D printable, bio compatible materials and stem cell delivery techniques for Qrons' traumatic brain injury treatment. Q

FOR IMMEDIATE RELEASE INVESTOR AND MEDIA CONTACT Qrons Inc. Mr. Jonah Meer E: [email protected] P: 786-620-2140 Qrons Announces Signing of Option Agreement with Dartmouth College Agreement will allow for further research developing innovative 3D printable, bio compatible materials and stem cell delivery techniques for Qrons' traumatic brain injury treatment. Qrons to also finance patent prosecution

Qrons Inc. Announces Launch of New Website Website Offers Visitors Insight into the Company's Innovative Multi-disciplinary Approach to Traumatic Brain Injuries

FOR IMMEDIATE RELEASE INVESTOR AND MEDIA CONTACT Qrons Inc. Mr. Jonah Meer E: [email protected] P: 786-620-2140 Qrons Inc. Announces Launch of New Website Website Offers Visitors Insight into the Company's Innovative Multi-disciplinary Approach to Traumatic Brain Injuries Miami, Florida, October 10, 2017/PR.com/ - Qrons Inc. (OTCPK: QRON) ("Qrons " or the "Company"), a preclinical biotechnology comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2017 QRONS INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2017 QRONS INC.

QRON / Qrons Inc. / Merfeld Ido - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 QRONS INC. (Name of Issuer) Shares of Common Stock, $0.0001 Par Value (Title of Class of Securities) 74737F101 (CUSIP Number) Jonah Meer Chief Executive Officer 777 Brickell Avenue, Suite 500 Miami, Florida 33131 (786)-620-2140 (Name, Address and Telephone Number of Person

QRON / Qrons Inc. / Meer Jonah - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 QRONS INC. (Name of Issuer) Shares of Common Stock, $0.0001 Par Value (Title of Class of Securities) 74737F101 (CUSIP Number) Jonah Meer Chief Executive Officer 777 Brickell Avenue, Suite 500 Miami, Florida 33131 (786)-620-2140 (Name, Address and Telephone Number of Person

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2017 Qrons Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55800 Commission File Number Qrons Inc. (Exact nam

Amendment to Articles of Incorporation (2)

AMENDMENT TO ARTICLES OF INCORPORATION OF BIOLABMART INC. BioLabMart Inc., a corporation organized and existing under the laws of the State of Wyoming, hereby certifies as follows: 1. The name of the corporation is BioLabMart Inc. The date of filing of its original Articles of Incorporation with the Secretary of State was August 22, 2016. 2. This Amendment amends Article I of the Articles of Incor

BioLabMart Inc. Announces Company Name Change to Qrons Inc.

FOR IMMEDIATE RELEASE INVESTOR AND MEDIA CONTACT Qrons Inc. Mr. Jonah Meer E: [email protected] P: 786-620-2140 BioLabMart Inc. Announces Company Name Change to Qrons Inc. MIAMI, Florida, August 11, 2017/PR.COM/ ? BioLabMart Inc, (OTC PINK/Trading Symbol: BLMB) ("the Company"), a startup preclinical stage biotechnology company, is pleased to announce that the company has changed its name to Qrons In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: □ Preliminary Information Statement □ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BIOLABMART INC. (Name of Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement □ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) □ Definitive Information Statement BIOLABMART INC. (Name of Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 3, 2017 BIOLABMART INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 3, 2017 BIOLABMART INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOLABMART INC. (Exact name of registrant as sp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOLABMART INC. (Exact name of registrant as specified in its charter) Wyoming 81-3623646 (State of incorporation or organization) (I.R.S. Employer Identification No.) 777 Brickell Avenue Suite 500

QRON / Qrons Inc. 10-Q - Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 333- 216650 Commission File Number BIOLABMART INC. (E

As filed pursuant to Rule 424(b)(3) Registration No. 333-216650 PROSPECTUS BIOLABMART INC. 1,124,000 Shares of Common Stock $0.0001 par value 562,000 Shares of Common Stock $0.0001 par value Issuable upon Exercise of Warrants

As filed pursuant to Rule 424(b)(3) Registration No. 333-216650 PROSPECTUS BIOLABMART INC. 1,124,000 Shares of Common Stock $0.0001 par value and 562,000 Shares of Common Stock $0.0001 par value Issuable upon Exercise of Warrants This prospectus relates to the offer and sale from time to time by the selling stockholders named in this prospectus of up to 1,124,000shares of our common stock $0.0001

BIOLAB MART INC. 777 Brickell Avenue Suite 500 Miami, Florida 33131

BIOLAB MART INC. 777 Brickell Avenue Suite 500 Miami, Florida 33131 May 8, 2017 BY EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Attention: Suzanne Hayes Assistant Director Office of Healthcare and Insurance Re: BioLab Mart Inc. Registration Statement on Form S-1 (File Number 333-216650) Dear Ms. Hayes: In accordance with Rule

As filed with the Securities and Exchange Commission on April 21 , 2017

As filed with the Securities and Exchange Commission on April 21 , 2017 Registration No.

Brenner & Associates, PLLC 147 Woodbine Road Roslyn Heights, New York 11577 Telephone: (917) 282-4272

Brenner & Associates, PLLC 147 Woodbine Road Roslyn Heights, New York 11577 Telephone: (917) 282-4272 nbrenneresq@gmail.

BioLabMart Inc. 777 Brickell Ave Suite 500 Miami, Florida 33131

BioLabMart Inc. 777 Brickell Ave Suite 500 Miami, Florida 33131 April 17, 2016 BY EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes Assistant Director Office of Healthcare and Insurance Re: BioLab Mart Inc. Registration Statement on Form S-1 Filed on March 13, 2017 File Number 333-216650 Dear Ms. Hayes: This

$10,000 8% Convertible Debenture Agreement, dated September 1, 2016, between the Company and CubeSquare LLC (1)

NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

Articles of Incorporation of the Company (1)

Form of Subscription Agreement for the Company's Regulation D private offering which closed January 27, 2017 (1)

SUBSCRIPTION AGREEMENT SECTION 1 1.1 Subscription. The undersigned, intending to be legally bound, hereby irrevocably subscribes for and agrees to purchase the number of shares of common stock Par Value $.0001 of BioLabMart Inc., a Wyoming company (the "Company") indicated on the signature page hereof. The undersigned understands that the shares are being offered and sold (the ?Offering?) in a pri

Form of Common Stock Purchase Warrant for the Company's Regulation D private offering which closed January 27, 2017 (1)

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

As filed with the Securities and Exchange Commission on March 13, 2017

As filed with the Securities and Exchange Commission on March 13, 2017 Registration No.

2016 Stock Option and Stock Award Plan (1)

BIOLABMART, INC. 2016 STOCK OPTION AND STOCK AWARD PLAN (this “PLAN”) 1. Definitions Each of the following terms shall have the respective meanings set forth below for purposes of this Plan, whether employed in the singular or plural unless the particular context in which said term is used clearly indicates otherwise: (a) “Administrator” shall mean, during the entire term of this Plan, the person

License and Research Funding Agreement, dated December 14, 2016, between the Company and Ariel University R&D Co., Ltd. (1)

LICENSE AND RESEARCH FUNDING AGREEMENT This License Agreement is entered into as of this 14th day of December, 2016, by and between BioLabMart Inc.

Certificate of Designation of Series A Preferred Stock (1)

Bylaws of the Company (1)

BYLAWS FOR BIOLABMART INC. Article I. Offices Principal Office Location Section 1.01. The corporation's principal office shall be located at 1900 Purdy Avenue, #1907, Miami Beach, Florida 33139 and may have offices at other places that are designated by the Board of Directors. Article II. Board of Directors Responsibility of the Board of Directors Section 2.01. The business and affairs of the corp